These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 2054231

  • 1. Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy.
    Bickerstaff DR, O'Doherty DP, McCloskey EV, Hamdy NA, Mian M, Kanis JA.
    Bone; 1991; 12(1):17-20. PubMed ID: 2054231
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
    Shane E, Jacobs TP, Siris ES, Steinberg SF, Stoddart K, Canfield RE, Bilezikian JP.
    Am J Med; 1982 Jun; 72(6):939-44. PubMed ID: 6211978
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy.
    Zysset E, Ammann P, Jenzer A, Gertz BJ, Portmann L, Rizzoli R, Jaquet-Müller F, Pryor-Tillotson S, Bonjour JP, Burckhardt P.
    Bone Miner; 1992 Sep; 18(3):237-49. PubMed ID: 1392697
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia.
    Wüster C, Schöter KH, Thiébaud D, Manegold C, Krahl D, Clemens MR, Ghielmini M, Jaeger P, Scharla SH.
    Bone Miner; 1993 Aug; 22(2):77-85. PubMed ID: 8251767
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
    Body JJ, Borkowski A, Cleeren A, Bijvoet OL.
    J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
    van Breukelen FJ, Bijvoet OL, van Oosterom AT.
    Lancet; 1979 Apr 14; 1(8120):803-5. PubMed ID: 86043
    [Abstract] [Full Text] [Related]

  • 13. Therapy of malignancy-associated hypercalcemia: 1983.
    Stewart AF.
    Am J Med; 1983 Mar 14; 74(3):475-80. PubMed ID: 6219580
    [Abstract] [Full Text] [Related]

  • 14. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
    Thiébaud D, Jaeger P, Jacquet AF, Burckhardt P.
    J Clin Oncol; 1988 May 14; 6(5):762-8. PubMed ID: 3367184
    [Abstract] [Full Text] [Related]

  • 15. Chronic lymphocytic leukemia and hypercalcemia: treatment with dichloromethylene diphosphonate.
    Siris ES, Grossbard L, Halper JP, Blume RS, Jacobs TP.
    Metab Bone Dis Relat Res; 1988 May 14; 5(2):61-3. PubMed ID: 6231452
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE.
    J Clin Oncol; 1997 Jan 14; 15(1):131-8. PubMed ID: 8996134
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton.
    Siris ES, Hyman GA, Canfield RE.
    Am J Med; 1983 Mar 14; 74(3):401-6. PubMed ID: 6219577
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.